Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug

Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis

Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit

Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis